Patterns of Thyroid-Stimulating Hormone Test After GLP-1 RAs Initiation in Patients on Levothyroxine: A Trial Emulation Study
Doctors often miss checking thyroid levels in diabetes patients starting weight-loss drugs, a practical gap that could affect medication dosing for millions.
A Medicare claims study of 5,370 matched T2DM patients found no difference in TSH monitoring rates between GLP-1 RA and SGLT-2i initiators despite GLP-1 agents causing greater weight loss likely requiring thyroid dose re-titration. This quality gap in real-world monitoring has direct clinical implementation implications for patients on levothyroxine starting GLP-1 therapy.
What the study was
- Study design
- Retrospective cohort / target trial emulation (Medicare data; n=5,370 matched)
- Population
- Adults ≥65 with T2DM on stable levothyroxine; US Medicare 15% sample 2011-2020
- Sample size
- 5370
- Category
- Public Health
- Maturity
- Validated
- Journal
- Journal of Clinical Endocrinology and Metabolism
Why it surfaced
Actionable quality gap identified in real-world practice: GLP-1 RA initiators on levothyroxine not getting appropriate TSH follow-up. Large Medicare sample, target trial emulation design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.